Conference Coverage

Anticoagulation not routinely needed after TAVR: ADAPT-TAVR

Publish date: April 4, 2022

 

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Transfusions, readmissions higher for patients with CLL after cardiac surgery
MDedge Hematology and Oncology
Cardiogenic shock teams again tied to lower mortality
MDedge Hematology and Oncology
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
MDedge Hematology and Oncology
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
MDedge Hematology and Oncology
Exercise reduces arm and shoulder problems after breast cancer surgery
MDedge Hematology and Oncology
ACC, AHA issue new coronary revascularization guideline
MDedge Hematology and Oncology
Who benefits most from device PFO closure after a stroke?
MDedge Hematology and Oncology
What does a pig-to-human heart transplant mean for medicine?
MDedge Hematology and Oncology
CVS Caremark formulary change freezes out apixaban
MDedge Hematology and Oncology
Silver lining emerges for embolic protection in post-TAVR stroke
MDedge Hematology and Oncology